SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- AltheaDx, Inc. ("AltheaDx" or the "Company"), a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced the appointment of Dr. Juan-Sebastian Saldivar as Chief Medical Officer. Additionally, the Company announced the appointment of Dr. Mark Gold to the board of directors.
"Dr. Saldivar's clinical and molecular diagnostic expertise will provide added depth to our medical and clinical affairs services. We are excited to welcome him to the executive leadership team of AltheaDx," said Greg Hamilton, Chief Executive Officer of AltheaDx. "We are confident that Dr. Saldivar's experience will prove invaluable to the AltheaDx team and our customers as we continue to expand the reach of our pharmacogenetic testing services."
"We are pleased to add Dr. Gold, in addition to the three directors announced in October, to our board of directors, which strengthens the depth of expertise and perspective at this important stage of AltheaDx's growth," added François Ferré, Ph.D., co-founder of AltheaDx and co-Chairman of the Company's board of directors.
Prior to joining AltheaDx, Dr. Saldivar served as Vice President of Clinical Services and Medical Affairs at Sequenom Laboratories, a provider of noninvasive prenatal testing services and wholly owned subsidiary of Sequenom, Inc. From July 2003 to March 2012, Dr. Saldivar filled various roles including Director of Molecular Diagnostics at City of Hope National Medical Center, a National Cancer Institute, while also teaching as a Clinical Associate Professor in the Department of Pathology from January 2010 to March 2012. Dr. Saldivar also served as Director of Clinical Laboratory Services at Perlegen Sciences, Inc., a biotechnology company, from February 2009 to November 2009. Dr. Saldivar completed fellowships in Medical Genetics and Clinical Molecular Genetics at the Harvard/Partners Center for Human Genetics and Genomics. He is a Fellow of the American College of Medical Genetics, and a member of the International Society for Prenatal Diagnosis, Association for Molecular Pathology, American Society of Human Genetics, and the College of American Pathologists. Dr. Saldivar earned his M.D. from the University of Texas Southwestern Medical School and his B.A. from Boston University.
Dr. Gold has more than four decades of experience in basic research, clinical research and translating research into clinical practice, and has been a pioneer in translational neuroscience research for more than three decades. From 1990 until his retirement in June 2014 he was a Professor, Distinguished Professor and Chairman at the University of Florida. He has served as a consultant to banks, private equity firms, global pharmaceutical companies, and venture capital firms on devices, pharmaceuticals and health care delivery. He has served on the boards of directors of Viewray, Inc., a privately held MR-guided cancer radiation therapy company, and AxoGen, Inc., a NASDAQ-traded medical technology company dedicated to peripheral nerve repair. Dr. Gold's qualifications to serve on the board of directors include his expertise in medical neuroscience and medical technology, in-depth knowledge of medication development and the pharmaceutical industry, and extensive experience in business and management. Dr. Gold completed his residency in psychiatry at Yale-New Haven Hospital and Yale University School of Medicine. He earned his M.D. from the University of Florida College of Medicine and his B.A. from Washington University in St. Louis.
AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix pharmacogenetic testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-accredited, CLIA-certified laboratory located in San Diego, CA.
Forward Looking Statements
This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
CONTACT: Kristen Nungesser ICR, Inc. (646) 277-1261 email@example.comSource:AltheaDx, Inc.